In this presentation, Dario Ghoddousi, VP Product Management, Compliance Solutions at QuintilesIMS and Ned Mumtaz, Practice Leader Life Sciences at qordata provide an overview of the implementation of the EFPIA disclosure code, the discrepancies in reporting requirements of member countries and areas of challenges. The presentation will further provide a detailed overview of reported EFPIA physician spend numbers, consent rates and the initiatives being taken by companies to increase the rate of consent.
Presentation by Maria Stylianidi, Member of the Board of Directors of the Hellenic Single Public Procurement Authority (HSPPA), Greece, on the organisation of the national procurement review system, Tbilisi, 6-7 November 2019.
The spending caps of public pharmaceutical spending, the role of the Italian Medicines Agency (AIFA), the payback system and the court cases of the pharma industry. It’s definitely time for a comprehensive reform of the pharmaceutical spending governance mechanism, which for now won’t happen: any reform will be a matter for the next Cabinet, that will be elected in March.
In this presentation, Dario Ghoddousi, VP Product Management, Compliance Solutions at QuintilesIMS and Ned Mumtaz, Practice Leader Life Sciences at qordata provide an overview of the implementation of the EFPIA disclosure code, the discrepancies in reporting requirements of member countries and areas of challenges. The presentation will further provide a detailed overview of reported EFPIA physician spend numbers, consent rates and the initiatives being taken by companies to increase the rate of consent.
Presentation by Maria Stylianidi, Member of the Board of Directors of the Hellenic Single Public Procurement Authority (HSPPA), Greece, on the organisation of the national procurement review system, Tbilisi, 6-7 November 2019.
The spending caps of public pharmaceutical spending, the role of the Italian Medicines Agency (AIFA), the payback system and the court cases of the pharma industry. It’s definitely time for a comprehensive reform of the pharmaceutical spending governance mechanism, which for now won’t happen: any reform will be a matter for the next Cabinet, that will be elected in March.
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
Getting the deal through life sciences russia 2015Lidings Law Firm
Produced annually by UK publishers Law Business Research Ltd., this 2015 edition of Getting the Deal Through: Life Sciences has been fully revised and updated to cover the key issues of current applicable regulation, including full analysis of important aspects of cross-border transactions and international law. With contributions from leading practitioners active in 26 jurisdictions worldwide, Lidings’ attorneys have authored exclusive coverage of Russian regulation of the life sciences sector, including those issues of most direct relevance to the firm’s major pharmaceutical clients.
As the UK Government prepares to publish the 'Repeal Bill' to give legal effect to the UK's withdrawal from the European Union, this paper looks at the possible implications for pharmaceuticals regulation. The paper by Andrew Hollingsworth gives a short overview of the current EU regulatory framework and looks at some of the options and potential outcomes in the forthcoming UK-EU negotiations.
In the pharmaceutical industry, patents are the preeminent incentive for innovation in developing new drugs. But patents aren’t the whole story; regulatory agencies also offer different forms of exclusivity—enforced by the agencies themselves—to encourage different forms of innovation in the industry. This panel discussed actual and potential roles for those rewards in the context of developing new drugs, new uses for old drugs, and new ways to make drugs, in both the United States and the European Union.
Alvaro de Ferranti - presentation for the European Ibogaine Conference Vienna...Alvaro de Ferranti
I was honoured to be invited to present at the European Ibogaine Conference in Vienna, September 2017. Here are some slides from the event.
If there was another way of kick-starting your recovery journey from your addiction and substance misuse problem, would you dare try it? We bridge the gap by combining our tailored version of the 12steps, CBT, Ibogaine (optional) and Holistic Therapies. We are proud to be pioneering the new generation of Rehab Centres. Why wait? Make the call!
www.tabularasaretreat.com Tel+351965751649
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
Getting the deal through life sciences russia 2015Lidings Law Firm
Produced annually by UK publishers Law Business Research Ltd., this 2015 edition of Getting the Deal Through: Life Sciences has been fully revised and updated to cover the key issues of current applicable regulation, including full analysis of important aspects of cross-border transactions and international law. With contributions from leading practitioners active in 26 jurisdictions worldwide, Lidings’ attorneys have authored exclusive coverage of Russian regulation of the life sciences sector, including those issues of most direct relevance to the firm’s major pharmaceutical clients.
As the UK Government prepares to publish the 'Repeal Bill' to give legal effect to the UK's withdrawal from the European Union, this paper looks at the possible implications for pharmaceuticals regulation. The paper by Andrew Hollingsworth gives a short overview of the current EU regulatory framework and looks at some of the options and potential outcomes in the forthcoming UK-EU negotiations.
In the pharmaceutical industry, patents are the preeminent incentive for innovation in developing new drugs. But patents aren’t the whole story; regulatory agencies also offer different forms of exclusivity—enforced by the agencies themselves—to encourage different forms of innovation in the industry. This panel discussed actual and potential roles for those rewards in the context of developing new drugs, new uses for old drugs, and new ways to make drugs, in both the United States and the European Union.
Alvaro de Ferranti - presentation for the European Ibogaine Conference Vienna...Alvaro de Ferranti
I was honoured to be invited to present at the European Ibogaine Conference in Vienna, September 2017. Here are some slides from the event.
If there was another way of kick-starting your recovery journey from your addiction and substance misuse problem, would you dare try it? We bridge the gap by combining our tailored version of the 12steps, CBT, Ibogaine (optional) and Holistic Therapies. We are proud to be pioneering the new generation of Rehab Centres. Why wait? Make the call!
www.tabularasaretreat.com Tel+351965751649
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 4: Collaboration within and between countries
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
Matheson partners Michael Finn and Robert O'Shea co-author the Ireland chapter for Getting The Deal Through: Life Sciences 2016.
Reproduced with permission from Law Business Research Ltd. This article was first published in Getting the Deal Through: Life Sciences 2016.
Allen frances dsm5 - Selling Sickness Conference 2010
Josée hansen igz
1.
2.
3. Competing interests Supervision and law enforcement in the Netherlands | 7 October 2010 public health needs <–> market driven phase IV study <–> seeding trials information <–> promotion clinical support <–> gifts clinical guidelines <–> disease mongering training <–> influencing
4. The Dutch way Introductie stafmedewerkers | 27 september 2010 Minister SG DG DG DG IG Public health Health care Long term care Medical products CBG CCMO Lareb
5.
6.
7.
8. Regulators in the Netherlands Supervision and law enforcement in the Netherlands | 7 October 2010 health product Health Products (HP) Non-prescription Medicines (OTC) Prescription Only medicines (POM) Medical Devices (MD) regulator Inspection Board for the Public Promotion of Medicines (KOAG) - Minor violations of law All violations of Code of Conduct - - Code of conduct for pharmaceutical advertising (CGR) - - Minor violations of law All violations of Code of Conduct - Health care Inspectorate - Recurrent minor violations of law All major violations of law Recurrent minor violations of law All major violations of law -
9. Collaboration: how it could be done Supervision and law enforcement in the Netherlands | 7 October 2010 Suspected violation is reported to HCI / CGR / KOAG Case handled by HCI Case handled by CGR Case handled by KOAG Infringement is ceased Case closed
10. Real life: parallel tracks Supervision and law enforcement in the Netherlands | 7 October 2010 Suspected violation is reported to HCI / KOAG HCI / KOAG assesses case and decides on appropriate regulator Case handled by HCI Case handled by CGR Case handled by KOAG Infringement is ceased Infringement is continued / repeated Secondary handling by HCI Case closed Suspected violation is reported to CGR Case handled by CGR Infringement is ceased Infringement is continued / repeated Secondary handling by HCI Case closed All cases regarding promotion directed at health care professionals All cases regarding promotion directed at the public